The authors concluded that selenium supplementation was associated with decreased risk of Kashin-Beck disease in children living in areas with low selenium levels. The evidence was limited and further research was needed. Given methodological limitations in the available studies, small sample sizes and uncertainties around the meta-analysis, the reliability of the authors' conclusions is unclear.
Study selection
Randomised controlled trials (RCT) and prospective non-randomised controlled trials that investigated the effects of selenium supplementation through any route and at any dosage compared to placebo or no treatment on rates of KashinBeck disease in children with under 18 years were eligible for inclusion. Studies of selenium supplementation in conjunction with vitamin E, vitamin C or both combined were excluded. Studies of adult and child participants were included if it was possible to isolate the data on the children.
Included RCTs were of selenium tablets of varying dosages and unknown duration compared to placebo in children aged between three and 13 years from Kashin-Beck disease endemic areas with or without Kashin-Beck disease. Included RCTs reported Kashin-Beck disease incidence rates or the case number of Kashin-Beck disease diagnosed using X-ray or Yonghou Scientific Survey group diagnosis criteria. Follow up ranged from one to three years.
Included prospective non-RCTs were of selenium salt, selenium tablet, selenium-iodine salt, selenium water and selenium crop spraying or fertiliser in varying dosages and unknown duration compared to placebo or no treatment in children between birth and 16 years in Kashin-Beck disease endemic regions. Included studies reported on the number of participants with Kashin-Beck disease or the incidence of Kashin-Beck disease measured using X-ray or recognised criteria. Follow up ranged from 10 months to six years. Some studies also reported on adverse events. Two reviewers independently selected the studies for the review at both abstract and full text stages. Disagreements were resolved by consensus.
Assessment of study quality
Methodological quality of the RCTs was assessed according to Cochrane guidelines focusing on randomisation, allocation concealment, blinding and follow-up using the description of blinding and allocation concealment by Wu and Liu (2007) (see Other Publications of Related Interest). The quality of non-RCTs was assessed using a checklist by Deeks et al (2003) . At least two reviewers independently assessed the methodological quality of the included studies; the authors stated only that disagreements were resolved by consensus without explicitly reporting how many reviewers performed the quality assessment.
Data extraction
The number of cases of Kashin-Beck disease in previously healthy children was extracted for the treatment and control groups in each study and used to calculate the odds ratio with corresponding 95% confidence intervals (CI). Two
